INTRODUCTION
============

The brain consists of a large and complex organism-specific network of neurons. A fundamental question in neurobiology is where and how the structure of this network is encoded in each organism\'s genome, i.e. how individual neurons acquire unique identities that enable them to create highly-specific synaptic connections, leading to the formation of an organism-specific network. There are several well-established examples for such mechanisms: the olfactory system, in which individual olfactory neurons express only 1 out of 1300 olfactory receptor genes, and establish connections based on the receptor expressed ([@gkr1260-B1]), and the Down-Syndrome-Cell-Adhesion-Molecules (Dscam) that regulate neural circuit formation in *Drosophila* ([@gkr1260-B2; @gkr1260-B3; @gkr1260-B4]). In mammals, it was hypothesized that the precise patterns of neuronal connectivity are largely determined by neuronal membrane molecules called protocadherins (*Pcdh*), which promote specific interneuron connections. These molecules are encoded by the clustered Protocadherin (*Pcdh*) genes ([@gkr1260-B5; @gkr1260-B6; @gkr1260-B7; @gkr1260-B8; @gkr1260-B9; @gkr1260-B10; @gkr1260-B11]) that represent the largest subgroup in the cadherin superfamily ([@gkr1260-B12],[@gkr1260-B13]). The *Pcdh* genes are present in all known vertebrate genomes, including mammals, chicken, zebrafish, fugu, and coelacanth ([@gkr1260-B13]) and are highly conserved in mammals. The *Pcdh* genes were shown to be highly expressed during neural development, creating Pcdh proteins that are concentrated in the synaptic region. As the brain matures, the expression level of the *Pcdh* genes decreases ([@gkr1260-B10],[@gkr1260-B12],[@gkr1260-B14; @gkr1260-B15; @gkr1260-B16; @gkr1260-B17]). Gene-knockout studies have demonstrated that *Pcdh* gene products play a crucial role in proper axonal projection, synaptic formation and neuronal survival ([@gkr1260-B18],[@gkr1260-B19]).

*Pcdh* genes are located on human chromosome 5 ([@gkr1260-B13]) and on mouse chromosome 18 ([@gkr1260-B20],[@gkr1260-B21]). In each neuron, *Pcdh* genes are expressed monoallelically, each allele is independently regulated, i.e. one variable exon is expressed from the paternal chromosome and another variable exon from the maternal chromosome, creating a combinatorial expression at the cell level ([@gkr1260-B22],[@gkr1260-B23]). There are 52 tandem-arranged *Pcdh* genes in human that are divided into three families: *Pcdh*α (15 genes), *Pcdh*β (16 genes), and *Pcdh*γ (21 genes), which are further subdivided into *Pcdh*γa and *Pcdh*γb ([@gkr1260-B21]).

In the *Pcdh*α and *Pcdh*γ families, each gene has a specific variable exon ([@gkr1260-B24]) that is linked to three constant exons (a structure similar to that of immunoglobulins and T-cell-receptors). In the *Pcdh*β family, each gene includes a variable exon only. Linking of a specific variable exon with the three constant exons in the *Pcdh*α and *Pcdh*γ genes is done by alternative splicing (as opposed to gene recombination used in immunoglobulin genes). Prior to splicing, each precursor mRNA transcribed by the *Pcdh*α and *Pcdh*γ genes, is of high molecular weight, since it includes all downstream variable exons ([@gkr1260-B25]). During splicing, only the 5′-most variable exon is *cis*-spliced to the first constant exon to generate functional mRNAs ([@gkr1260-B13],[@gkr1260-B21],[@gkr1260-B26]).

Assuming that each cluster expresses, at the most, one gene from each allele, this unusual *Pcdh* expression may provide sufficient diversity to represent at least 1.5 million unique individual cell labeling (see materials and methods for the calculation). Each *Pcdh* variable exon is preceded by a distinct promoter, and all promoters contain a similar highly conserved core motif of ∼22 bp, the conserved sequence element (CSE) ([@gkr1260-B26],[@gkr1260-B27]). In addition, long-range *cis*-regulatory DNA elements in the *Pcdh*α gene cluster, HS5-1 and HS7, were identified and found to possess enhancer activity in reporter assays ([@gkr1260-B28]). Interestingly, both elements are conserved among vertebrates and also include a CSE. The *Pcdh*α genes are likely to be regulated by methylation as the transcription of specific *Pcdh*α genes was found to be significantly correlated with the methylation state of the first exon. On the other hand, mosaic or mixed methylation states of the CSE in the promoters were associated with both active and inactive transcription ([@gkr1260-B29]). Presently, the mechanisms underlying promoter choice and promoter activity are largely unknown.

In the present study, we investigated the mechanism underlying *Pcdh* gene transcription. Using bioinformatics methods, we have identified a sequence element located near the CSE that is highly conserved among mammals but, unlike the Common Sequence Element, is unique to each of the 52 *Pcdh* genes. We termed the identified element specific sequence element (SSE). The 20-bp-long SSE is essential for transcription and can activate transcription only in the presence of the CSE. We have purified the complex that binds the SSE--CSE region and identified CCTC-binding factor (CTCF) as a factor that binds the promoters of *Pcdh* genes through the common CSE and the SSE elements. Remarkably in the context of *Pcdh* genes CTCF plays an essential positive role in transcription. Our findings point to CTCF as a factor that is essential for *Pcdh* expression and probably for the control of neuronal connectivity.

MATERIALS AND METHODS
=====================

Bioinformatics analysis of the *Pcdh* promoters
-----------------------------------------------

Regulatory elements such as enhancers and locus control regions are highly conserved among different mammalian species. To identify regions containing putative DNA elements that regulate *Pcdh* expression, we compared the genomic DNA upstream to the first exon of each gene in the three *Pcdh* families (α, β and γ). Human, chimp, mouse, rat and dog promoter regions from −1000 relative to the TSS were retrieved from UCSC Genome Browser (<http://genome.ucsc.edu/>). This analysis revealed new conserved sequences located immediately upstream of the previously identified CSE. These regions are more conserved among species (orthologs) than among family members within the same species (paralogs) ([Supplementary Figure S1](http://nar.oxfordjournals.org/cgi/content/full/gkr1260/DC1)).

For calculation of combinational *Pcdh* diversity, we used binomial coefficients: the number of ways to choose *K* elements from *N* is

The calculation is as follows: the number of ways to choose two variable exons from 13 (for *Pcdh*α), 13!/11! × 2!, multiplied by choose 2 from 15 (for *Pcdhβ*), 15!/13! × 2!, multiplied by choose 2 from 19 (for *Pcdh* γ), 19!/17! × 2!, is equal to 1.5 million unique labels. This calculation does not take into account that the Pcdhα and Pcdhγ proteins also form oligomers ([@gkr1260-B30]), which can further increase the molecular diversity at the cell surface.

Plasmid construction
--------------------

The promoter regions of the α6 and α3 genes (−217 and −219 relative to translation start site, respectively) were cloned by genomic PCR into pGL3-Basic (Promega) using the HindIII site. The α6, α3 and deletions promoters region was amplified using primers that introduce a HindIII restriction site at the end of the PCR products ([Supplementary Data S1](http://nar.oxfordjournals.org/cgi/content/full/gkr1260/DC1), primers 17--20 and 28--30); For the mutatgenesis of the αSSE linker addition, we used oligonucleotides containing the mutated or linker sequences flanked by KpnI in 5′ and NheI in 3′ sites located immediately upstream and downstream, respectively, to the αSSE site ([Supplementary Data S1](http://nar.oxfordjournals.org/cgi/content/full/gkr1260/DC1), primers 21--27 and 31--51). All plasmids constructed in this study were verified by DNA sequencing.

Transient transfection assays and RNA analysis
----------------------------------------------

The 293T and SH-SY5Y cells were maintained and transfected as described ([@gkr1260-B31]). HEC1-B cells (human endometrial cancer cell line) were maintained in Minimum essential medium (Eagle) with 2 mM [l]{.smallcaps}-glutamine and Earle\'s BSS adjusted to contain 1.5 g/l sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate, 90%; fetal bovine serum, 10%. All transfections were performed by using Lipofectamine 2000 (Invitrogen).

For reporter assays, subconfluent cells were transfected in a 24-well plate using 750 ng luciferase reporter plasmid, 25 ng CMV-GFP, 50 ng Rous sarcoma virus (RSV) promoter-driven *Renilla* luciferase reporter plasmid, At 24 h after transfection, cells were harvested and their luciferase and *Renilla* luciferase activities were measured. The mean and the SD values were determined for each construct based on four independent transfections.

For determining the effect of CTCF depletion on the activity of the reporter gene, SH-SY5Y cells were grown on 10-well plates and transfected with CTCF siRNA (Origene, cat \# SR307273), or Scrambled siRNA-Scr (Origene, cat \# SR30004) as a negative control at a concentration of 10 nM. Twenty-four hours later, the cells were split to 12-well plates. After an additional 72 h (96 h after siRNA transfection) the cells were transfected with 1.5 µg luciferase reporter plasmid, 50 ng CMV-GFP, 100 ng Rous sarcoma virus (RSV) promoter-driven *Renilla* luciferase reporter plasmid. At 24 h after second transfection, cells were harvested and their luciferase and *Renilla* luciferase activities were measured. The mean and the SD values were determined for each construct based on four independent transfections.

For determining the effect of CTCF depletion on the activity of the endogenous *Pcdh* mRNA levels, HEC1-B cells were grown on 6-well plate and tranfected with 10 nM CTCF siRNA (Origene, cat \# SR307273), or Scrambled siRNA-Scr (Origene, cat \# SR30004) as a negative control. One hundred and twenty hours later total RNA was extracted using Tri-reagent (MRC Inc.). cDNAs were synthesized from 1 µg of total RNA in a 20 µl reaction volume using the SuperScript III Reverse Transcriptase (Invitrogen) and random primers as per the manufacturer\'s instructions. Quantitative real time PCRs were performed in duplicate using the Applied Biosystems 7300 Real-Time PCR System (Applied Biosystems). Independent PCRs were performed using the same cDNA for genes of interest and the GAPDH gene which serves as an internal control, using the SYBR® Green PCR Master Mix (Applied Biosystems). Gene-specific primers were designed for the genes of interest and for the GAPDH gene using Primer Express® software (Applied Biosystems). The sequences of the primer pairs are listed in [Supplementary Data S3](http://nar.oxfordjournals.org/cgi/content/full/gkr1260/DC1), primers 1--5.

Electrophoretic mobility shift assay and 'super-shift' assay
------------------------------------------------------------

DNA oligonucleotides containing the α6SSE--CSE or α3SSE--CSE or α12SSE--CSE or SP1 sequences ([Supplementary Data S2](http://nar.oxfordjournals.org/cgi/content/full/gkr1260/DC1), oligonucleotides 1--2, 10 and 18) were fluorescently labeled on the 5′-end with Cy5, HEX, or FAM (Integrated DNA Technologies, Inc). The oligonucleotides were annealed in 20 µl in a concentration of 10 pmol/µl and used as probes to the reaction. The binding reactions containing 2 µg of poly(dI-dC) (Sigma), 2 µg of poly(dA-dT) (Sigma), 10 µM Zn and 10 µg of HEC-1B/SH-SY5Y nuclear extract prepared as described previously ([@gkr1260-B32]), with binding buffer consisting of 25 mM HEPES (pH 7.9), 50 mM KCl, 1 mM DTT and 10% glycerol. The reaction mix was incubated on ice for 10 min after which 500 fmol probe was added for an additional 20 min. Competitor doubled stranded DNAs (50×, 25 pmol) were added prior to the addition of the probe ([Supplementary Data S2](http://nar.oxfordjournals.org/cgi/content/full/gkr1260/DC1), oligonucleotides 3--9, 11--17 and 19--21). The muted doubled stranded DNA sequences have the same sticky ends. The reactions were separated by native electrophoresis at 4°C in a 6.5% polyacryamide gel with 1× Tris--Glycine buffer at 185 V. The gel visualized with the Typhoon 9400 instrument (Amersham Biosciencs). Supershift assays were carried out with antibodies to CTCF (Abcam ab70303, ab37477, ab37478), BUB3 (Abcam ab4180) and YY1 (Abcam ab12132). Methylation assays were carried out using methylated competitor DNA in 50- to 100-fold excess. The competitor DNA was synthesized with methyl Cs instead of Cs in two places of CpG sequences (Integrated DNA Technologies, Inc).

Fractionation of nuclear extract by Macro-prep high S cation exchange column
----------------------------------------------------------------------------

SH-SY5Y nuclear extract prepared as described previously was incubated with washed Macro-prep high S cation exchange support beads (Bio-Rad) at 4°C for 30 min. Flow through fractions where collected after separation from the beads using centrifugation at 500 G for 4 min. Elution with 200, 400 and 800 mM KCl buffers containing 25 mM HEPES (pH 7.9), 1 mM EDTA, 1 mM dithiothreitol and 10% glycerol was performed using centrifugation at 500 G for 4 min. Dialysis over night was performed on eluted fractions using 10 KDa dialysis bag (Thermo scientific) in dialysis buffer described previously. A fraction of all the eluted samples was analyzed on SDS--PAGE gradient acryl amid gel 4--12.5% (GEBA) with 1× Tris--Glycine 0.1% SDS buffer at 130 V for 1 h.

Affinity purification and western blot
--------------------------------------

Affinity magnetic FG plain beads were prepared as follows: oligonucleotides of the α6 and α6_mut sequences, with phosphorylated GGGG or CCCC at the 5′-end of the forward and reverse complement, respectively, were synthesized (Integrated DNA Technologies, Inc) ([Supplementary Data S2](http://nar.oxfordjournals.org/cgi/content/full/gkr1260/DC1), oligonucleotides 22--23).

The oligonucleotides were annealed and then ligated using T4 ligase 5 U/µl (Fermentas) using the manufacturer ligation buffer for 16 h in 4°C to generate a concatamer of 5--15 repeats. The muted sequence has the same sticky ends. The ligated DNA was then phenol--chloroform extracted and desalted using Nick column (GE healthcare) equilibrated with water. The ligated samples were run on agarose electrophoresis gel to verify that the ligation process has succeeded ([Supplementary Figure S5](http://nar.oxfordjournals.org/cgi/content/full/gkr1260/DC1)). The ligated DNA was then immobilized to 10 mg magnetic FG plain beads (Tamagawa seiki Co. Ltd) by incubation at 50°C for 24 h. The immobilized beads where then washed with 2.5 M KCl and incubated with 1 M ethanoamine (pH 8) over night for masking. Prior to purification the immobilized beads were washed three times using a magnetic stand in washing buffer containing 25 mM HEPES (pH 7.9), 100 mM KCl, 1 mM EDTA, 1 mM dithiothreitol and 10% glycerol. Crude nuclear extract or elution fraction collected from cation fractionation was incubated with beads at 4°C for 4 h using rotator in binding buffer containing 2 µg of poly(dI-dC) (Sigma), 1 µg of poly(dA-dT) (Sigma) consisting of 25 mM HEPES (pH 7.9), 50 mM KCl, 1 mM dithiothreitol and 10% glycerol. Beads were then washed four times using a magnetic stand with washing buffer previously described. Bound proteins were then eluted from the beads using a magnetic stand with elution buffer at room temperature for 30 min consisting of, 25 mM HEPES (pH 7.9), 1 M KCl, 1 mM EDTA, 1 mM dithiothreitol and 10% glycerol. Dialysis over night was performed on a fraction of the sample using dialysis bag (Thermo scientific) in dialysis buffer described previously. A fraction of the sample was sent to Mass-spec analysis for protein identification. Tandem mass spectrometry (MS/MS) analysis coupled with liquid chromatography (LC) was carried out by the Smoler Proteomics Center (Faculty of Biology, Technion, Israeli Institute of Technology, Israel). Top candidates are those proteins that were identified by mass spectrometry analysis following DNA affinity purification only from the wild-type SSE--CSE but not detected at the elution of the mutated SSE--CSE sequences in three repeats.

For western blot, a fraction of the sample was analyzed on SDS--PAGE gradient acryl amid gel 4--12.5% (GEBA) with 1× Tris--Glycine 0.1% SDS buffer at 130 V for 1 h, transferred to nitrocellulose membranes blots, and probed with anti-CTCF (Abcam ab70303) and anti-Histone H3 (Abcam ab1791) antibodies. Secondary antibodies consisted of goat anti-rabbit conjugated to IRDye800 or to IRDye680 (LI-COR Biosciences), were used and then the membrane was scanned for infrared signal using the Odyssey Imaging System (LI-COR Biosciences).

Production of CTCF Proteins *in vitro*
--------------------------------------

Full-length human CTCF (pET-7.1) and the 11 ZF CTCF-binding domain (pET-11ZF) which were verified in several papers ([@gkr1260-B33],[@gkr1260-B34]), were kindly donated by V. Lobanenkov (National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA). These plasmids along with Luciferase T7 Control DNA, which serves as a positive control, were synthesized using the TnT® T7 Quick Coupled Transcription/Translation System (Promega). The *in vitro* synthesized proteins were labeled with a fluorescently labeled lysine amino acid using the FluoroTect GreenLys labeling system according to the manufacturer's instructions (Promega). We verified the identity of the plasmids using restriction enzyme analysis and SDS--PAGE analysis which verified that the synthesized proteins have the correct molecular mass ([Figure 6](#gkr1260-F6){ref-type="fig"}A).

RESULTS
=======

Identification of a novel *cis*-element in the promoters of the *Pcdh* genes
----------------------------------------------------------------------------

In order to identify the regulatory elements that control *Pcdh* expression, we first looked for additional segments in the *Pcdh* cluster that are conserved among mammalian species, namely: chimp, mouse, rat, dog and human. The 1000 bp upstream of each of the 52 *Pcdh* V-exons from the above species were aligned. This analysis revealed novel highly conserved regions located immediately upstream of the previously defined conserved sequence element, CSE ([@gkr1260-B16],[@gkr1260-B35],[@gkr1260-B36]) ([Figure 1](#gkr1260-F1){ref-type="fig"}). Interestingly, unlike the CSE which is common to the promoters of all families, these conserved regions, although they may have common regions, are unique to each gene ([Supplementary Figure S1](http://nar.oxfordjournals.org/cgi/content/full/gkr1260/DC1)). We therefore termed these regions, Specific Sequence Elements (SSE). All 52 occurrences of the CSE and the 52 unique SSEs are highly conserved in mammals ([Supplementary Figure S1](http://nar.oxfordjournals.org/cgi/content/full/gkr1260/DC1)). The SSEs we analyze consists of α(1 to 13)SSE, β(1 to 16)SSE, γa(1 to 12)SSE and γb(1 to 7)SSE. The *PcdhαC1, αC2, PcdhγC3*, *γC4*, and *γC5* were omitted from this analysis. Figure 1.Schematic representation of the *Pcdh* gene cluster promoters. Genomic organization of the *Pcdh* genes, with tandem variable region exons (blue), promoter regions (turquoise) and constant region exons (red). Each promoter region contains an SSE followed by a CSE, which is common to all genes of the family. V, variable region; C, constant region.

The αSSE is essential for *Pcdh* transcriptional activity
---------------------------------------------------------

To investigate the transcriptional control of the *Pcdh* gene clusters we chose to focus on the *Pcdhα* family. We first examined the expression of all the *Pcdhα* genes in HEC-1B, 293T and SH-SY5Y cell lines by RT--PCR and found that each of these cell lines expresses at least one *Pcdhα* gene ([Figure 2](#gkr1260-F2){ref-type="fig"}A). While the CSE has been previously shown to be important for the transcription of *Pcdh* genes ([@gkr1260-B16],[@gkr1260-B35],[@gkr1260-B36]) we wished to examine the function of the newly discovered αSSE in the *Pcdhα* family, and for this purpose *Pcdhα6* was selected. The α6 promoter containing the α6SSE and the CSE was cloned in front of a luciferase reporter gene ([Figure 2](#gkr1260-F2){ref-type="fig"}B). Upon transfection into HEC-1B, 293T and SH-SY5Y cell lines, this promoter fragment displayed a high transcriptional activity compared to the promoter-less (basic) reporter gene in all these cells ([Figure 2](#gkr1260-F2){ref-type="fig"}C, WT columns). When the α6SSE or α6SSE plus CSE were deleted (Δα6SSE or Δα6SSE-ΔCSE, respectively) the transcriptional activity was severely diminished in all the cell lines ([Figure 2](#gkr1260-F2){ref-type="fig"}C). Likewise, point mutations in the CSE (CSEmut) also diminished transcription ([Figure 2](#gkr1260-F2){ref-type="fig"}C), in agreement with previous reports ([@gkr1260-B16],[@gkr1260-B35],[@gkr1260-B36]). We also examined the SSE function of the *Pcdhα3* gene promoter (α3SSE) and found it to be essential for α3 promoter activity ([Figure 2](#gkr1260-F2){ref-type="fig"}C, fourth panel). These findings confirm that CSE is crucial but not sufficient for *Pcdh* expression and also requires in addition the SSE to drive the *Pcdh* transcription. Figure 2.αSSE and CSE activate transcription cooperatively. (**A**) The expression profile of all the *Pcdhα* genes in HEC-1B, 293T and SH-SY5Y cell lines by RT--PCR, ([Supplementary Figure S2](http://nar.oxfordjournals.org/cgi/content/full/gkr1260/DC1)). Gray and black boxes indicate for absence or presence of *Pcdhα* mRNA, respectively. (**B**) A scheme depicting the sequences of α6SSE--CSE WT and mutants (b--d). (**C**) WT (α6SSE--CSE and α3SSE--CSE) and the mutated promoters (fused to firefly luciferase reporter gene) were transfected into HEC-1B, 293T and SH-SY5Ycell lines together with RSV-*Renilla* that serves as internal control. The parental pGL3-basic (Basic) was also transfected as a control. Twenty-four hours post-transfection firefly and *renilla* luciferase activities were measured. The normalized results are the mean of at least four independent experiments (±SD).

To investigate α6SSE further, α6SSE mutants were created by site-directed mutagenesis ([Figure 3](#gkr1260-F3){ref-type="fig"}A, Mut1--Mut4). The α6SSE Mut2 construct reduced the transcriptional activity to the level of the promoter-less (basic) construct, Mut3--Mut4 promoters caused reduction of 70% while Mut1 did not have a significant effect on the transcription level ([Figure 3](#gkr1260-F3){ref-type="fig"}A). Figure 3.Sequence requirements for the function of α6SSE--CSE as transcriptional elements. (**A**) Successive blocks within αSSE (underlined) in the α6SSE--CSE promoter were mutated (Mut1-Mut4). The wild-type and mutated constructs were transfected into HEC-1B, 293T and SH-SY5Y cell lines together with RSV-*Renilla* that serves as internal control. Twenty-four hours post-transfection firefly and *Renilla* luciferase activities were measured. The normalized results are the mean of at least four independent experiments (±SD). (**B**) Linkers of 5, 10 and 15 bp (5nLinker, 10nLinker and 5nLinker) were introduced between α6SSE and CSE and their effect was analyzed as described earlier.

To determine whether the distance between the SSE and the CSE is important for their function we increased the spacing between the SSE and the CSE sites by 5, 10 and 15 bp, which corresponded to ∼0.5, 1 and 1.5 helical turns (5nLinker, 10nLinker and 5nLinker). The results revealed that the transcriptional activity was reduced to the level of promoter-less construct in all the examined cell lines, regardless of the size of the spacer that was introduced ([Figure 3](#gkr1260-F3){ref-type="fig"}B). These findings suggest that the specific location of the SSE relative to the CSE is crucial for their promoter activity.

Identification of a specific DNA-binding complex that is αSSE and CSE dependent
-------------------------------------------------------------------------------

To investigate further the mechanism underlying αSSE--CSE activity we analyzed the proteins that interact with the αSSE--CSE region. A fluorescently labeled DNA fragment comprising the α6SSE--CSE sequence was incubated with a nuclear extract prepared from HEC-1B cells and then subjected to electrophoresis mobility shift assay (EMSA). Two major complexes were formed between the DNA and the extract ([Figure 4](#gkr1260-F4){ref-type="fig"}A). The complexes were competed out by excess (50-fold) of unlabeled α6SSE--CSE DNA ([Figure 4](#gkr1260-F4){ref-type="fig"}A, lane 2) but not by excess of the non-relevant Sp1 sequence DNA ([Figure 4](#gkr1260-F4){ref-type="fig"}A, lane 3). Figure 4.Gene-specific complex binds to the αSSE--CSE. (**A**) EMSA using HEC-1B cell nuclear extract and a fluorescently labeled double stranded oligonucleotide containing αSSE--CSE sequence as a probe. Lane 1, the probe is incubated with HEC-1B nuclear extract. Competitor DNAs were added to the reactions in lanes 2 and 3 as indicated on the top. The sequences of the oligonucleotides used for binding and competition are shown on the top. (**B**) αSSE--CSE display cooperative DNA binding activity. EMSA using HEC-1B cell nuclear extract and a fluorescently labeled double stranded oligonucleotide containing α6SSE--CSE as a probe. Unlabeled competitor DNAs were added to the reactions as indicated in the top panel. The sequences of the oligonucleotides used for binding and competition are shown earlier. (**C**) The specific complex is shown to bind with high affinity to α6SSE--CSE. EMSA using SH-SY5Y cell nuclear extract and a fluorescently labeled double stranded oligonucleotide containing α6SSE--CSE as a probe. Unlabeled αSSE--CSE sequences of *Pcdhα* genes as competitor DNAs were added in excess to the reactions as indicated in the top panel. The sequences of the oligonucleotides used for binding and competition are shown earlier. (**D**) Competition assay for α3SSE--CSE and to α12SSE--CSE specific complex. EMSA using HEC-1B cell nuclear extract and a fluorescently labeled double stranded oligonucleotide comprising of α3SSE--CSE as a probe in the left panel and α12SSE--CSE as a probe in the right panel. Unlabeled competitor DNAs were added to the reactions as indicated in the top panel. The specific DNA complex and the free probes are indicated by arrows.

To examine the importance of the α6SSE--CSE region, competition assays with excess of various types of unlabeled DNA were performed: (i) DNA with mutations in either α6SSE, CSE or both (ii) DNA with spacing between the α6SSE and CSE regions. We found that the complex was not competed out by excess DNA containing mutations in either the CSE ([Figure 4](#gkr1260-F4){ref-type="fig"}B, lane 4), α6SSE ([Figure 4](#gkr1260-F4){ref-type="fig"}B, lane 5), both ([Figure 4](#gkr1260-F4){ref-type="fig"}B, lane 6) or mut2 α6SSE ([Figure 4](#gkr1260-F4){ref-type="fig"}B, lane 7). In addition, a 5-bp linker between the α6SSE and CSE also failed to compete ([Figure 4](#gkr1260-F4){ref-type="fig"}B, lane 8) indicating that the spacing between the elements is important for binding. These results are consistent with the effect of the mutations and the linker on promoter activity ([Figure 3](#gkr1260-F3){ref-type="fig"}B) and suggest that the two elements are critical for the DNA binding complex.

A recent study reported that the CSE shows mosaic methylation or hypo-methylation, regardless of transcription level ([@gkr1260-B29]). Our findings also show that CpG methylation of the αSSE--CSE regions does not affect complex formation ([Supplementary Figure S3](http://nar.oxfordjournals.org/cgi/content/full/gkr1260/DC1)).

Next, we carried out competition assays with a similar DNA sequence derived from the other promoters of the *Pcdhα* cluster (with α1SSE--CSE, α2SSE--CSE, ... , α13SSE--CSE) and of the *Pcdhγ* cluster, γA2SSE--CSE. Remarkably, the complex was not competed out by excess of most of the *Pcdh*α SSE--CSE and not by excess the *Pcdh* γA2SSE--CSE ([Figure 4](#gkr1260-F4){ref-type="fig"}C). We similarly analyzed the complex that binds to the α3SSE--CSE ([Figure 4](#gkr1260-F4){ref-type="fig"}D, left panel) and the α12SSE--CSE ([Figure 4](#gkr1260-F4){ref-type="fig"}D, right panel). A competition assay was performed, in which the α3SSE--CSE or α12SSE--CSE labeled DNA probes were competed out by excess of unlabelled DNA from parallel regions of other *Pcdh* genes ([Figure 4](#gkr1260-F4){ref-type="fig"}D). The α3SSE--CSE and α12SSE--CSE complexes failed to be competed out by SSE--CSE regions corresponding to other genes in the cluster. The results suggest the existence of a unique component for each SSE that confers specificity of the complex that binds to each promoter of the *Pcdhα.*

Purification of the αSSE--CSE complex and its identification by mass spectrometry
---------------------------------------------------------------------------------

To further characterize αSSE--CSE binding proteins, we developed a purification scheme composed of two chromatographic steps ([Figure 5](#gkr1260-F5){ref-type="fig"}A). First, SY5Y nuclear extract was loaded onto Macro-prep high S cation exchange column and proteins were eluted by increased salt concentrations. The fractions where analyzed by EMSA and the α6SSE--CSE specific complex was found in the 800 mM KCl fraction ([Figure 5](#gkr1260-F5){ref-type="fig"}B, lane 2), resulting in ∼3-fold enrichment. Next, the 800 mM fraction was subjected to DNA affinity chromatography using magnetic nanoparticles ([@gkr1260-B37]). The affinity matrix was generated by chemical cross-linking immobilization to the magnetic nanoparticles the α6SSE--CSE or the α6SSE--CSE_mut DNAs that were multimerized. The α6SSE--CSE_mut DNA was mutated in both the α6SSE and the CSE elements and served as negative control. After incubation of the 800 mM enriched fraction with the DNA-beads, unbound and eluted fractions were analyzed by EMSA using α6SSE--CSE DNA ([Figure 5](#gkr1260-F5){ref-type="fig"}B). It was apparent that the α6SSE--CSE was efficiently depleted from the unbound fraction of the α6SSE--CSE DNA containing beads ([Figure 5](#gkr1260-F5){ref-type="fig"}B, lane 3). In contrast, in the unbound fraction of the α6SSE--CSE_mut the specific complex was still present ([Figure 5](#gkr1260-F5){ref-type="fig"}B, lane 4). Consistently, the elution of the α6SSE--CSE DNA affinity contained the α6SSE--CSE complex whereas the complex was completely absent from the elution of the mutated DNA beads ([Figure 5](#gkr1260-F5){ref-type="fig"}B, lanes 5 and 6). This purification step resulted in approximately a 13-fold enrichment. To identify the proteins that specifically bind to α6SSE--CSE, the affinity eluted fractions of both α6SSE--CSE and α6SSE--CSE_mut DNA were subjected to comparative mass-spectrometry. The top significant candidates from mass-spectrometry analysis of proteins that specifically bind to the α6SSE--CSE are depicted in [Table 1](#gkr1260-T1){ref-type="table"}. Figure 5.Purification of αSSE--CSE DNA-bound proteins. (**A**) Schematic diagram of the purification procedure. (**B**) Binding activity of α6SSE--CSE to the purified fractions was assessed by EMSA using the α6SSE--CSE as a probe. Lane 1, the probe is incubated with SH-SY5Y nuclear extract. Lane 2, with the 800 mM KCl elution fraction of the cation exchange. The flow-through (lanes 3 and 4) and the eluted fractions (lanes 5 and 6) of the affinity purification stage of α6SSE--CSE DNA (α6) and α6SSE--CSE_mut DNA (α6_mut), respectively. (**C**) Identification of the proteins that bind to the α6SSE--CSE using specific antibodies according to the MS results. Lane 1, the probe is incubated with SH-SY5Y nuclear extract; lanes 2 and 3 EMSAs were carried out in the presence of two different CTCF antibodies, lane 4 YY1 antibody; lane 5 BUB3 antibody. The specific DNA complexes, 'super-shift' (SS) complexes and the free probes are indicated by arrows. (**D**) Western blot analysis of CTCF protein in the flow-through and in the eluted fractions of the affinity purification stage of α6SSE--CSE DNA (α6) and muted DNA (α6_mut). Figure 6.Recombinant CTCF binds specifically to several αSSE--CSE DNA sequences. (**A**) SDS--PAGE analysis of the full-length CTCF and 11ZF CTCF-binding domain proteins, which were synthesized *in vitro* from the pET-7.1 and pET-11ZF constructs. Luciferase T7 Control DNA no plasmid were used for positive and negative controls, respectively. The *in vitro* synthesized proteins are fluorescently labeled. Positions of the molecular mass protein markers (on the left) are indicated. The white arrows point to the positions of the *in vitro* synthesized proteins. (**B**) EMSAs using *in vitro*-translated luciferase, human CTCF full-length (FL), 11ZF or SH-SY5Y nuclear extract with αSSE--CSE sequences as probes. Lanes 1--3, α12SSE--CSE probe, lanes 4--6, α3SSE--CSE probe and lanes 7--14, α6SSE--CSE probe. The proteins used for binding and the competitor DNA are indicated on the top. The specific complexes between the probe and the recombinant proteins or the nuclear extract are indicated by arrows. Table 1.Significant candidate proteins which specifically bind to the α6SSE--CSE identified by mass-spectrometry analysisAccession NumberProtein nameGene symbolFunctionNumber of peptides1P49711Transcriptional repressorCTCFTranscription regulator and chromatin insulator42O43684Mitotic checkpoint proteinBUB3Involved in spindle checkpoint function33O14776Transcription elongation regulator 1TCR1Regulates transcriptional elongation and pre-mRNA splicing34Q9P016Thymocyte nuclear protein 1THYN1May be involved in the induction of apoptosis35P18615Negative elongation factor ENELFEPart of a complex which represses RNA polymerase II transcript elongation26A6NFI3Zinc finger protein 691ZN316May be involved in transcriptional regulation37P51858Hepatoma-derived growth factorHDGFActs as a transcriptional repressor28Q96K17Transcription factor BTF3 homolog 4BT3L4Basic transcription factor---unknown29P06748NucleophosminNPMInvolved in diverse cellular processes such as ribosome biogenesis, centrosome duplication, protein chaperoning, histone assembly, cell proliferation, and regulation of tumor suppressors TP53/p53 and ARF210Q9H5H4Zinc finger protein 768ZN768May be involved in transcriptional regulation211O60828Polyglutamine-binding proteinPQBP1Involved with transcription activation212Q6DD87Zinc finger protein 787ZN787May be involved in transcriptional regulation213Q86U70LIM domain-binding protein 1LDB1Binds to the LIM domain of a wide variety of LIM domain-containing transcription factors314A6NFI3Zinc finger protein 316ZN316May be involved in transcriptional regulation315Q99417C-Myc-binding proteinMYCBPStimulates the activation of E box-dependent transcription by MYC516Q5T6F2Ubiquitin-associated protein 2UBAP2The function of this protein has not been determined517Q6PJG2Uncharacterized protein C14orf43CN043unknown6

To test which of the proteins identified by the mass-spectrometry binds specifically to α6SSE--CSE, we examined whether antibodies against these factors interfere or 'super-shift' the α6SSE--CSE complex in EMSA. Three different anti-CTCF antibodies were added to the reaction mix. The first anti-CTCF antibody (ab70303) eliminated the specific transcription complex ([Supplementary Figure S4](http://nar.oxfordjournals.org/cgi/content/full/gkr1260/DC1)) while the two other anti-CTCF antibodies (ab37477, ab37478) retarded the migration of the specific transcription complex and a slower migration was formed instead of the original one ([Figure 5](#gkr1260-F5){ref-type="fig"}C, lanes 2 and 3). Interestingly this was the case also for another, non-specific complex which was super-shifted with anti-BUB3 antibody ([Figure 5](#gkr1260-F5){ref-type="fig"}C, lane 5). In addition we used an antibody for YY1, a transcription factor that appeared in the mass-spectrometry results in both the α6SSE--CSE and in the control α6SSE--CSE_mut DNA. The addition of anti-YY1 to the reaction mix retarded another complex that binds to the α6SSE--CSE fluorescently labeled probe ([Figure 5](#gkr1260-F5){ref-type="fig"}C, lane 4), which was not specific to these elements. Inspection of the sequence α6SSE--CSE DNA that was used as a probe revealed the presence of a perfect YY1 binding site at the 3′-end of the fragment which was unaffected by the mutations. These results imply that there are several protein-DNA complexes formed between the nuclear extract and the α6SSE--CSE labeled DNA probe and provide validation that the purification scheme we utilized led to the identification of relevant proteins. Next, we examined the effect of the CTCF antibody on the complexes formed with a DNA fragment from other members of the *Pcdhα* family (α12SSE--CSE and α3SSE--CSE) or from another family (γa2SSE--CSE). The same pattern, which eliminated the specific complex (ab70303), was observed with all these probes ([Supplementary Figure S4](http://nar.oxfordjournals.org/cgi/content/full/gkr1260/DC1)). These findings are consistent with *in vivo* data as analysis of the recently released ChIP-seq data from UCSC genome-browser and from Handoko *et al.* ([@gkr1260-B38]) which revealed that CTCF was associated with the promoter of each of the *Pcdh* genes *in vivo*.

To further validate that CTCF binds specifically to the SSE--CSE we performed western blot following affinity purification using anti-CTCF (Abcam ab70303). The CTCF was depleted from the unbound fraction of the WT but not the mutated DNA beads. Consistently, CTCF was exclusively eluted from the WT and not in the muted affinity column ([Figure 5](#gkr1260-F5){ref-type="fig"}D).

To gain further support that SSE--CSE is directly bound by CTCF, we used *in vitro* transcribed and translated full-length human CTCF and 11ZFs fragments ([Figure 6](#gkr1260-F6){ref-type="fig"}A) in EMSA. A specific retarded complex was observed using 11ZFs protein for DNA promoters of several members of the *Pcdhα* family: α6SSE--CSE ([Figure 6](#gkr1260-F6){ref-type="fig"}B, lane 8), α12SSE--CSE ([Figure 6](#gkr1260-F6){ref-type="fig"}B, lane 1) and α3SSE--CSE ([Figure 6](#gkr1260-F6){ref-type="fig"}B, lane 4). Recombinant luciferase protein prepared by the same *in vitro* translation reaction was used as a negative control for site-specific DNA-binding experiments ([Figure 6](#gkr1260-F6){ref-type="fig"}B, lanes 2, 4, 13). No complex observed, however, with the full-length CTCF ([Figure 6](#gkr1260-F6){ref-type="fig"}B, lane 7) possibly since the DNA binding domain of CTCF in the full-length context is masked or not properly folded. The specificity of the interaction was confirmed by a competition assays with excess of unlabeled DNA sequence of WT ([Figure 6](#gkr1260-F6){ref-type="fig"}B, lane 9) and DNA with mutations in either CSE ([Figure 6](#gkr1260-F6){ref-type="fig"}B, lane 10) α6SSE ([Figure 6](#gkr1260-F6){ref-type="fig"}B, lane 11), or both ([Figure 6](#gkr1260-F6){ref-type="fig"}B, lane 12).

The *in vitro* data provides strong evidence for the novel interaction of CTCF with highly conserved CSE-SSE sequences present in the *Pcdh* gene promoters. These sequences were sufficient for function, for binding and for biochemical purification of CTCF.

CTCF is essential for *Pcdhα* expression
----------------------------------------

To investigate further the role of CTCF in regulation of *Pcdh* expression, we tested whether knocking down the endogenous CTCF would affect *Pcdh* promoter activity. SH-SY5Y cells were transfected with siRNA against CTCF or a scrambled negative control. Seventy-two hours post-transfection *Pcdhα6* promoter-luciferase reporter genes were transfected into these cells and luciferase activity was determined 24 h later. Down-regulation of endogenous CTCF by siRNA-CTCF but not scrambled siRNA was confirmed by western blot analysis with anti-CTCF (ab70303) ([Figure 7](#gkr1260-F7){ref-type="fig"}A). The results clearly show that CTCF siRNA but not scrambled siRNA severely diminished the luciferase activity directed by the WT *Pcdhα6* promoter by \>3-fold ([Figure 7](#gkr1260-F7){ref-type="fig"}A). This reduction in luciferase activity was specific to *Pcdh* because siRNA-CTCF did not affect the luciferase activity driven by the SV40 promoter ([Figure 7](#gkr1260-F7){ref-type="fig"}A). Figure 7.CTCF is essential for *Pcdhα* gene-expression. (**A**) Knocking down CTCF down-regulated the expression of α6 promoter-driven reporter gene. Top panel, western blot analysis with either CTCF or H3 antibodies of SH-SY5Y cells transfected with siRNA-CTCF scrambled siRNA or mock. Bottom panel, 72-h post-siRNA transfction, luciferase reporter gene driven by *Pcdhα6*, basic and SV40 promoters were transfected into SH-SY5Y cell lines together with RSV-*Renilla* that served as internal control. Twenty-four hours post-transfection firefly and *Renilla* luciferase activities were measured. The normalized results are the mean of four independent experiments (±SD). (**B**) Knocking down CTCF down-regulated the expression of endogenous *Pcdhα* genes. Top panel, western blot analysis with either CTCF or H3 antibodies of HEC-1B cells transfected with siRNA-CTCF scrambled siRNA or mock. Bottom panel, 120-h post-siRNA transfection, mRNA level was measured using relative quantification for endogenous *Pcdha6*, *Pcdha12* genes and *c-Myc* gene as a positive control.

To gain further support for the involvement of CTCF in the transcriptional activity of endogenous *Pcdh* mRNA, we measured the mRNA levels of *Pcdhα6* and *Pcdhα12* in HEC1-B cells that selectively expressed these genes, following knock down of CTCF by siRNA ([Figure 7](#gkr1260-F7){ref-type="fig"}B). In these cells CTCF protein level was decreased by 80% whereas its levels were unchanged by the scrambled siRNA. Down-regulation of CTCF caused similar reduction in the levels of the endogenous *Pcdhα6* and *Pcdhα12* mRNA levels. As a positive control, we selected the *c-My*c gene, for which CTCF was known to act as a repressor ([@gkr1260-B39]), and found that *c-My*c levels were up-regulated as expected. These findings strongly suggest that CTCF acts as a major activator of *Pcdh* genes.

DISCUSSION
==========

In the present study we have identified a novel specific element (SSE) found in the promoters of all 52 *Pcdh* genes, positioned immediately upstream of each CSE. In contrast to the CSE, SSEs are rather unique sequences and much less conserved between paralogs of the same gene family. We have shown that *Pcdh* promoter activity was governed by the combined activity of the newly identified SSE and the CSE. Thus, while CSE is indeed crucial for transcription, it is definitely not sufficient. Using DNA binding assay we found a nuclear complex that specifically interacts with αSSE--CSE *in vitro*. Subsequently, we have isolated and identified CCTC-binding-factor (CTCF) as the protein that binds and specifically binds and regulates the SSE--CSE in each promoter region of the *Pcdh*. First, we found that CTCF binds in a highly specific manner to the promoter region of several representative genes from the *Pcdhα* and *Pcdh*γ families *in vitro*. Second, knocking down CTCF down-regulated the expression of endogenous active *Pcdh* genes as well as *Pcdh* promoter-driven reporter gene. These findings suggest that CTCF binds to the promoters of the clustered *Pcdh* genes and is acting as a master positive regulator of all the *Pcdh* genes. Our findings are consistent with previous reports that show that binding of CTCF to the target site is methylation-independent ([@gkr1260-B40],[@gkr1260-B41]).

CTCF is a diverse protein and has a unique structure of 11 zinc-finger-DNA binding domains which are conserved among vertebrates. This distinct structure gives CTCF an exceptional degree of flexibility for DNA binding site recognition, which led to the description of CTCF as a 'multivalent' transcription factor ([@gkr1260-B42]). CTCF is known to perform numerous functions including enhancer blocking, X-chromosome inactivation, gene imprinting, monoallelic gene expression and promoter activation or repression ([@gkr1260-B42; @gkr1260-B43; @gkr1260-B44; @gkr1260-B45; @gkr1260-B46]). It has been demonstrated that CTCF can mediate contact between CTCF binding sites, to stabilize intra- and inter chromosomal long range interactions to affect transcription ([@gkr1260-B38],[@gkr1260-B47],[@gkr1260-B48]). Conditional CTCF Knock out models have demonstrated that CTCF affects transcription in enhancers of both beta and alpha Globin loci ([@gkr1260-B49],[@gkr1260-B50]), the HOX cluster ([@gkr1260-B51]), the XITE of the X-chromosome ([@gkr1260-B52]) and the EBV ([@gkr1260-B53]). Another recent study, which investigates the transcriptional activity in CTCF mutant limbs, has shown that the CTCF sites in RNA splicing may regulate the production of specific alternative transcript variants ([@gkr1260-B51]).

CTCF is known to interact with diverse protein partners that determine its specific function; hence, the regulation of CTCF activity might be achieved by neighboring factors bound to DNA. These partners factors include the RNA polymerases I, II and III, another zinc finger factor VEZF1 and the factors YY1, SMAD, TR and Oct4. Each of these seems to influence, modulate or determine the function of CTCF ([@gkr1260-B54]). Of particular interest to this study is YY1 which was shown to interact with CTCF and to function together in X-chromosome inactivation ([@gkr1260-B52]). YY1 is a ubiquitous four-zinc-finger transcription factor that has been implicated in biological processes such as embryogenesis, differentiation, cell proliferation and tumorigenesis ([@gkr1260-B55]). Surprisingly, in the course of our research YY1 were found to bind specifically to the SSE--CSE, most likely through a YY1 binding site that partially overlap the CSE of α6, α3 and α12. Although YY1 and CTCF appeared in our experiments as distinct complexes on EMSA, it is possible that under physiological conditions they bind cooperatively to the promoters of *Pcdhα* genes.

Considering that the *Pcdh* gene cluster contains several promoter elements in tandem, with only one or two are active, and the fact that *Pcdh* expression is monoallelic, it is possible that in addition to its ability to activate *Pcdh* transcription, it also has a central role in insulating nearby promoters in the monoallelic expression of *Pcdh* genes. Depending on the promoter context and cell background, CTCF may repress or activate transcription; however, its repression function predominates. We found that CTCF acts primarily as a positive transcription factor for the *Pcdh* genes. We cannot conclude from our results that the SSE dictates cell type specific expression. However, if we take into account the fact that CTCF is associated with most of the *Pcdh* promoters *in vivo* ([@gkr1260-B56],[@gkr1260-B57]) (according to the ChIP-seq data found in the UCSC genome browser), as well as in conserved enhancers HS5-1 ([@gkr1260-B28]) and HS16--20 ([@gkr1260-B58]), it may well be possible that CTCF also serves as a repressor that acts to silence the inactive *Pcdh* genes. However in these studies the exact site to which CTCF binds and the functional significance of CTCF for *Pcdh* expression were not addressed. This repression can be achieved through different conformation of DNA/CTCF-complexes (which CTCF binding to itself) that allow it to form chromatin hubs by selective intra- and interchromosomal interactions bridging together specific subsets of genomic CTCF sites. The divergence of the CTCF-binding sequences (as a result of unique SSEs) can serve as 'CTCF CODE' ([@gkr1260-B59],[@gkr1260-B60]) encrypting interactions with co-partner in a site specific manner (through the SSEs) and establishing structure-functional 3D organization involved in regulating the expression of individual *Pcdh* genes. The nature and composition of this co-partner is yet to be determined. Profiling the gene expression pattern of several different cell lines following profiling the DNA binding location of the CTCF and other candidate proteins will give us a predictive mechanistic model for the specific regulation of the *Pcdh* gene expression.

In summary, the expression of distinct *Pcdh* mRNAs in individual neurons is regulated by the activation or repression of subsets of promoters preceding individual genes. The choice of a gene included in a *Pcdh* mRNA appears to be a direct consequence of promoter selection. The mechanism of differential *Pcdh* promoter activation or repression in individual neurons is therefore likely to be a key step in regulating the cell-specific expression of distinct *Pcdh* genes. Our work is, therefore, another step forward in the effort to understand the mechanism for *Pcdh* gene expression, which may have significant implications on mammalian brain development. These findings may also have implications to human neuronal diseases linked to aberrant *Pcdh* function such as autism ([@gkr1260-B61]), bipolar disorder, schizophrenia ([@gkr1260-B62]), auditory deficiencies ([@gkr1260-B63]) and tumors ([@gkr1260-B64]).
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